×

Endocyte Announces Presentations at American Association for Cancer Research (AACR) 2015 Annual Meeting

WEST LAFAYETTE, Ind., April 10, 2015 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced that four posters will be presented by Endocyte scientists at the 2015 Annual Meeting of the American Association for Cancer Research (AACR) to be held in Philadelphia, April 18-22, 2015.

The presentation materials will be available on Endocyte's website following presentation at the conference.

Presentations are as follows:

Abstract #: 4393
Title:
Design and synthesis of novel conjugates for targeting the folate receptor: Exploiting cytotoxic GARFTase inhibitors for delivering additional chemotherapeutic payloads to cancer cells
When: Tuesday, April 21, 1 p.m. – 5 p.m. EDT
Session Title: Novel Drug Delivery Systems
Location: Poster Section 28; Poster Board Number 9
Abstract #: 4488
Title: Folate receptor targeted therapy using small molecule drug conjugates constructed with high affinity antifolate ligands
When: Tuesday, April 21, 1 p.m. – 5p.m. EDT
Session Title: Novel Targets 2
Location: Poster Section 31; Poster Board Number 15
Abstract #: 4495
Title: Small molecule approach for targeting tumor-associated macrophages via a functional FRβ
When: Tuesday, April 21, 1 p.m. – 5 p.m. EDT
Session Title: Novel Targets 2
Location: Poster Section 31; Poster Board Number 22
Abstract #: 5359
Title: Antitumor efficacy of EC1456 in patient derived xenograft models of ovarian, endometrial, NSCLC and TNBC
When: Wednesday, April 22, 8 a.m. – 12:00 p.m. EDT
Session Title: Drug Discovery
Location: Poster Section 28; Poster Board Number 19

About Vintafolide (EC145)

Vintafolide is an investigational proprietary, injectable, SMDC consisting of folate (vitamin B9) linked to a potent vinca alkaloid chemotherapy agent, desacetylvinblastine hydrazide (DAVLBH). Vintafolide is designed to target the chemotherapy agent to rapidly growing cancer cells that actively take up folate via the folate receptor. The folate receptor is expressed in a wide variety of cancers including ovarian cancer and non-small cell lung cancer.

About EC1456

EC1456 is an investigational proprietary, injectable, SMDC consisting of folate (vitamin B9) linked to a potent cytotoxic agent, tubulysin B hydrazide (TubBH). EC1456 is wholly owned by Endocyte. TubBH is a member of the tubulysin class of anti-neoplastic agents that inhibit the polymerization of tubulin into microtubules, a critical component during cell division. The targeting ligand folate, essential for cell division, has been investigated with vintafolide. EC1456 is currently being evaluated in a Phase 1 study in patients with advanced solid tumors (ClinicalTrials.gov Identifier: NCT01999738).

About Endocyte

Endocyte is a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases. Endocyte uses its proprietary technology to create novel SMDCs and companion imaging agents for personalized targeted therapies. The company's SMDCs actively target receptors that are expressed or over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly potent drugs into these cells. The companion imaging agents are designed to identify patients whose disease expresses the molecular target of the therapy and who therefore may be more likely to benefit from treatment. For more information, visit http://www.endocyte.com.

CONTACT: Stephanie Ascher, Stern Investor Relations, Inc. (212) 362-1200, stephanie@sternir.com

Source:Endocyte, Inc.